title: Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
authors.affiliation: Division of Medical Oncology, University of Colorado, Aurora, Colorado.
authors.forename: Joel P
authors.initials: JP
authors.lastname: Womack
authors.forename: Marileila
authors.initials: M
authors.lastname: Varella-Garcia
authors.forename: D Ross
authors.initials: DR
authors.lastname: Camidge
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005260:Female; D005784:Gene Amplification; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met